New HER2 Drug for Breast Cancer Stalled by FDA

The FDA said it needs more data the new antibody-drug conjugate (ADC) trastuzumab duocarmazine for use in advanced or metastatic breast cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/992001?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost